Cardiac Workup for Asymptomatic 65-Year-Old
For this asymptomatic 65-year-old patient, begin with cardiovascular risk assessment using a validated risk calculator (e.g., ASCVD Pooled Cohort Equation), followed by a standard fasting lipid profile—if the patient falls into intermediate risk (7.5-20% 10-year risk), coronary artery calcium scoring (CACS) is the single most valuable test to guide preventive therapy decisions. 1
Initial Risk Stratification
Start by calculating the 10-year ASCVD risk using traditional risk factors (age, sex, blood pressure, cholesterol levels, smoking status, diabetes). This quantitative risk estimate is the foundation for all subsequent decisions 1. At age 65, this patient likely falls into intermediate or higher risk categories based on age alone.
Standard Laboratory Assessment
Obtain a fasting lipid profile as the essential baseline test 1. This is the only lipid testing needed—advanced lipoprotein testing, apolipoprotein measurements, or particle size analysis provide no additional benefit for risk assessment 1.
Risk-Based Testing Strategy
For Low Risk (<5% 10-year risk):
- No additional cardiac testing needed
- Focus on healthy lifestyle maintenance
For Intermediate Risk (7.5-20% 10-year risk):
Coronary artery calcium scoring is the most appropriate next step 2. This is where most 65-year-olds will fall, and CACS provides superior risk stratification compared to all other noninvasive markers 2.
CACS Interpretation and Management:
CACS = 0: Reclassify to lower risk; statin therapy can be deferred with reassessment in 3-5 years. These patients have low event rates regardless of other risk factors 2
CACS 1-99: Modest reclassification; statin therapy is favored, especially for those >55 years (which includes this patient). The intermediate-risk group with CACS >0 has a 10.4% observed event rate 2
CACS ≥100 or ≥75th percentile for age/sex/race: Strong indication for statin therapy. Event rates reach ≥20 events per 1000 person-years, approximating secondary prevention populations 2
For High Risk (≥20% 10-year risk):
- Aggressive lifestyle modification plus statin therapy recommended
- CACS may still provide prognostic information but doesn't change management
Tests That Are NOT Indicated
Avoid these common pitfalls:
Resting ECG: Only Class IIb (may be considered) for risk assessment in asymptomatic adults without hypertension or diabetes—provides minimal additional information 1
Stress testing (exercise ECG, stress echo, or stress MPI): Not indicated for low- or intermediate-risk asymptomatic adults 1. Stress echocardiography specifically has a Class III (no benefit) recommendation for this population 1
Echocardiography: Only Class IIb for detecting left ventricular hypertrophy in intermediate-risk patients—not a first-line test 1
Advanced stress imaging: Stress myocardial perfusion imaging is not indicated unless the patient has diabetes, strong family history of CHD, or CACS ≥400 1. Even with CACS >400, this is only a weak recommendation (Class IIb) 2
Additional Considerations
C-reactive protein (CRP) measurement can be useful if the patient has LDL <130 mg/dL and is not on statins, without diabetes or chronic kidney disease, to help guide statin therapy decisions (Class IIa) 1.
Hemoglobin A1C may be reasonable for risk assessment if diabetes is not already diagnosed (Class IIb) 1.
Critical Clinical Context
The patient's anxiety about friends having MIs is understandable but doesn't change the evidence-based approach. Reassure the patient that systematic risk assessment is more valuable than symptom-driven or anxiety-driven testing. Most MIs occur in previously asymptomatic individuals, which is precisely why risk-based prevention strategies exist 2.
The 10-year ASCVD rate for ages 65-74 is approximately 8.3% 2, placing most 65-year-olds in intermediate risk where CACS provides the greatest clinical utility for personalizing preventive therapy.
Do not proceed directly to invasive testing or advanced imaging without first establishing risk category and, if appropriate, obtaining CACS. This stepwise approach maximizes benefit while minimizing unnecessary radiation exposure, cost, and potential for incidental findings that create patient anxiety 2.